News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab in HER2+ Breast Cancer
Jul 25, 2024, 20:48

Subcutaneous vs Intravenous Trastuzumab/Pertuzumab in HER2+ Breast Cancer

Dana-Farber’s Breast Oncology Center shared on X:

“New in JCO Oncology Practice:

Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial).

Full Text here.”

Source: Dana-Farber’s Breast Oncology Center/X

Breast Cancer

Authors: Adrienne G Waks, Emily L Chen, Noah Graham, Anna Mae Frey, Kenneth Almeida, Victoria Attaya, Cari Ryding, Ibrahim Abbass, Anita Fung, Jesse Sussell, Patricia Cortazar, Caroline Harvey, Denise Leth, Meredith Faggen, Natalie Sinclair, Jeanna Walsh, Nadine Tung, Sarah Sinclair, Steve Lo, Denise Yardley, Vicente Valero, Jane Meisel, Tarah J Ballinger, Sylvia Adams, Lisa A Carey, Julia K Rauch, Vandana G Abramson, Nicole O Williams, Wendy Y Chen, Jose P Leone, Susan T Schumer, Nabihah Tayob, Sara M Tolaney

Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial)

Anita Fung Anna Mae Frey Breast Cancer cancer Cari Ryding Caroline Harvey Dana-Farber’s Breast Oncology Center Denise Leth Denise Yardley Emily L Chen Here are the names with the numbers removed: Adrienne G Waks Ibrahim Abbass Jane Meisel JCO Oncology Practice Jeanna Walsh Jesse Sussell Jose P Leone Julia K Rauch Kenneth Almeida Lisa A. Carey Meredith Faggen Nabihah Tayob Nadine Tung Natalie Sinclair Nicole O Williams Noah Graham OncoDaily Oncology Patricia Cortazar pertuzumab Sara M. Tolaney Sarah Sinclair Steve Lo Susan T Schumer Sylvia Adams Tarah J Ballinger trastuzumab Vandana G Abramson Vicente Valero Victoria Attaya Wendy Y. Chen
Special Coverage
Blog
Nov 15, 2024, 21:44
Karen Humphreys won the Advocate of the Year from the Florida Society of Clinical Oncology - UF Health Cancer Center
Blog
Nov 15, 2024, 21:37
Margaret Foti: AACR Special Conference on Liquid Biopsy
Blog
Nov 15, 2024, 21:26
Johanna Joyce: An inspiring end to our Tumor Immunology and Immunotherapy
Blog
Nov 15, 2024, 21:21
Adjuvant immunotherapy in patients with resected GEJ cancer with high risk for recurrence
Blog
Nov 15, 2024, 21:09
Miriam Knoll: An in-person lung tumor board with Nagashree Seetharamu
Insight
Nov 15, 2024, 21:05
Get Ready for ESTRO2025 Pre-Meeting Courses
Insight
Nov 15, 2024, 21:03
Explore the latest in oncology at ESMOASIA24
Insight
Nov 15, 2024, 21:02
Robin Zon: Debate day 2 of COSA
Blog
Nov 15, 2024, 20:28
Long-Term Adverse Effects and Complications After Prostate Cancer Treatment
Blog
Nov 15, 2024, 19:31
What is proton beam therapy and how does it work - Atrium Health
Blog
Nov 15, 2024, 17:47
Nico Gagelmann: Current status and Future directions for CAR-T Therapy
Insight
Nov 15, 2024, 17:45
Osteopontin as a therapeutic target in Breast Cancer recurrence